Kyverna Therapeutics, Inc.
KYTX
$9.40
$0.040.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 30.01M | 137.19M | 135.93M | 127.43M | 112.47M |
| Gross Profit | -30.01M | -137.19M | -135.93M | -127.43M | -112.47M |
| SG&A Expenses | 36.11M | 34.40M | 35.70M | 33.22M | 29.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 169.83M | 171.59M | 171.63M | 160.65M | 141.50M |
| Operating Income | -169.83M | -171.59M | -171.63M | -160.65M | -141.50M |
| Income Before Tax | -161.31M | -160.99M | -158.70M | -145.42M | -127.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -161.31 | -160.99 | -158.70 | -145.42 | -127.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -161.31M | -160.99M | -158.70M | -145.42M | -127.48M |
| EBIT | -169.83M | -171.59M | -171.63M | -160.65M | -141.50M |
| EBITDA | -244.78M | -208.06M | -207.94M | -196.95M | -177.82M |
| EPS Basic | -3.66 | -3.72 | -3.67 | -3.37 | -3.46 |
| Normalized Basic EPS | -2.28 | -2.33 | -2.30 | -2.10 | -2.13 |
| EPS Diluted | -3.66 | -3.72 | -3.67 | -3.37 | -3.46 |
| Normalized Diluted EPS | -2.28 | -2.33 | -2.30 | -2.10 | -2.13 |
| Average Basic Shares Outstanding | 177.01M | 173.09M | 172.83M | 172.73M | 153.27M |
| Average Diluted Shares Outstanding | 177.01M | 173.09M | 172.83M | 172.73M | 153.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |